KEYNOTE-811: Latest Updates From ESMO 2024

Opinion
Video

Panelists discuss how KEYNOTE-811's study design and key findings presented at the European Society for Medical Oncology (ESMO) Congress 2024 demonstrate the potential impact of pembrolizumab plus trastuzumab and chemotherapy in HER2-positive gastric cancer treatment.

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
Adding Bevacizumab Improves PFS, But Not OS, in Advanced Biliary Tract Cancer

Adding Bevacizumab Improves PFS, But Not OS, in Advanced Biliary Tract Cancer

Sabrina Serani
November 6th 2024
Article

Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration of response in patients with advanced biliary tract cancer.

Read More

LaPelusa’s Journey in the Dynamic Field of GI Oncology

LaPelusa’s Journey in the Dynamic Field of GI Oncology

Jordyn Sava;Michael LaPelusa, MD
May 1st 2024
Podcast

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Listen

Lenvatinib/Pembrolizumab/TACE Regimen Improves PFS in Intermediate-Stage HCC

Lenvatinib/Pembrolizumab/TACE Regimen Improves PFS in Intermediate-Stage HCC

Jordyn Sava
October 28th 2024
Article

Josep M. Llovet, MD, PhD, discussed the updated data from the LEAP-012 trial in intermediate-stage hepatocellular carcinoma.

Read More

Unpacking the Latest Research in Gastrointestinal Cancers

Unpacking the Latest Research in Gastrointestinal Cancers

Nichole Tucker;Benjamin L. Schlechter, MD
February 15th 2023
Podcast

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

Listen

FDA Pushes Back Decision on Sotorasib/Panitumumab in Colorectal Cancer

FDA Pushes Back Decision on Sotorasib/Panitumumab in Colorectal Cancer

Sabrina Serani
October 18th 2024
Article

The FDA was expected to decide on the application of sotorasib and panitumumab for the treatment of metastatic colorectal cancer on October 17, 2024.

Read More

Trial of PT886 and Pembrolizumab Doses First Patient With Gastric/GEJ Cancer

Trial of PT886 and Pembrolizumab Doses First Patient With Gastric/GEJ Cancer

Jordyn Sava
October 10th 2024
Article

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with pembrolizumab.

Read More